Literature DB >> 30704667

Differentiating between hepatocellular carcinoma and intrahepatic cholangiocarcinoma using contrast-enhanced MRI features: a systematic review and meta-analysis.

M-W You1, S J Yun2.   

Abstract

AIM: To identify magnetic resonance imaging (MRI) features for differentiating hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (IHCC) and summarise their diagnostic accuracy.
MATERIALS AND METHODS: PubMed and EMBASE were searched for studies that employed MRI features to differentiate HCC from IHCC. Overlapping descriptors used to denote the same imaging finding in different studies were subsumed under a single feature. The pooled diagnostic accuracies, including the diagnostic odds ratios (DORs) and 95% confidence intervals (CIs) of the identified features, were calculated using a bivariate random-effects model.
RESULTS: In total, 1,370 patients with HCC and 687 patients with IHCC in 14 studies were included. Fifty-two descriptors were subsumed under 15 MRI features. Of these, 11 features were informative for differentiating HCC from IHCC. The five MRI features favouring HCC were capsule, arterial diffuse enhancement, portal venous washout, conventional washout, and intralesional fat; the six MRI features favouring IHCC were surface retraction, arterial rim enhancement, progressive enhancement, target appearance on diffusion-weighted and hepatobiliary phase (HBP) images, and bile duct dilatation. These features tended to show high specificity, but low sensitivity. Useful MRI features with high DORs (>20) were capsule (34; 95% CI, 5-215) and intralesional fat (23; 4-85) for HCC and arterial rim enhancement (31; 6-160), progressive enhancement (24; 8-73), and target appearance on HBP images (29; 3-261) for IHCC.
CONCLUSION: Eleven informative MRI features for differentiating HCC from IHCC were identified. These features will assist in the accurate diagnosis of these diseases and in disease outcome prediction.
Copyright © 2019 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30704667     DOI: 10.1016/j.crad.2018.12.016

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  3 in total

1.  DWI Combined With Hepatobiliary-Phase Enhanced Imaging Can Better Differentiate Cholangiocarcinoma From Atypical Liver Abscesses.

Authors:  Li-Hong Xing; Li-Yong Zhuo; Yu Zhang; Xi Ma; Ze-Peng Ma; Ying-Jia Zhao; Xiao-Ping Yin; Bu-Lang Gao
Journal:  Front Oncol       Date:  2022-05-13       Impact factor: 5.738

Review 2.  Liquid biopsy in cholangiocarcinoma: Current status and future perspectives.

Authors:  Gianluca Rompianesi; Marcello Di Martino; Alex Gordon-Weeks; Roberto Montalti; Roberto Troisi
Journal:  World J Gastrointest Oncol       Date:  2021-05-15

Review 3.  Gadoxetic acid magnetic-enhanced resonance imaging in the diagnosis of cholangiocarcinoma.

Authors:  Riccardo Inchingolo; Cesare Maino; Marco Gatti; Eleonora Tricarico; Michele Nardella; Luigi Grazioli; Sandro Sironi; Davide Ippolito; Riccardo Faletti
Journal:  World J Gastroenterol       Date:  2020-08-07       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.